Breaking Finance News

RBC Capital Markets issued a report on Enanta Pharmaceuticals Inc (NDAQ:ENTA), hiking its target to $54.00 earlier today

RBC Capital Markets bumped up the target price of Enanta Pharmaceuticals Inc (NDAQ:ENTA) to $54.00 indicating a possible upside of 0.20%.

Displaying a price of $45.08, Enanta Pharmaceuticals Inc (NDAQ:ENTA) traded 3.99% higher on the day. With the last close up 30.87% from the two hundred day average, compared with the Standard & Poor's 500 Index which has increased 0.04% over the date range. Enanta Pharmaceuticals Inc has recorded a 50-day average of $40.51 and a 200-day moving average of $34.25. 93,805 shares of the stock were exchanged, down from an average trading volume of 214,052

See Chart Below

Enanta Pharmaceuticals Inc (NDAQ:ENTA)

With a total market value of $0, Enanta Pharmaceuticals Inc has with a one year low of $22.17 and a 52 week high of $45.14 .

General Information About Enanta Pharmaceuticals Inc (NDAQ:ENTA)

Enanta Pharmaceuticals, Inc. is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV). It has discovered novel protease inhibitors that are members of the direct-acting-antiviral (DAA) inhibitor classes designed for use against the hepatitis C virus (HCV). These protease inhibitors, developed through its collaboration with AbbVie Inc. (AbbVie), include paritaprevir and glecaprevir (ABT-493). Its product candidates also include EDP-305, which is a farnesoid X receptor (FXR) agonist product candidate for NASH and PBC, and EDP-938, which is a clinical candidate for RSV.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.